Cargando…
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
The aim of this study was to provide a better insight into breast cancer response to chemotherapy. Chemotherapy improves outcome in breast cancer patients. The effect of cytotoxic treatment cannot be predicted for individual patients. Therefore, the identification of tumour characteristics associate...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747533/ https://www.ncbi.nlm.nih.gov/pubmed/12569384 http://dx.doi.org/10.1038/sj.bjc.6600749 |
_version_ | 1782172102482198528 |
---|---|
author | Faneyte, I F Schrama, J G Peterse, J L Remijnse, P L Rodenhuis, S van de Vijver, M J |
author_facet | Faneyte, I F Schrama, J G Peterse, J L Remijnse, P L Rodenhuis, S van de Vijver, M J |
author_sort | Faneyte, I F |
collection | PubMed |
description | The aim of this study was to provide a better insight into breast cancer response to chemotherapy. Chemotherapy improves outcome in breast cancer patients. The effect of cytotoxic treatment cannot be predicted for individual patients. Therefore, the identification of tumour characteristics associated with tumour response and outcome is of great clinical interest. We studied 97 patients, who received anthracycline-based neoadjuvant chemotherapy. Tumour samples were taken prior to and after chemotherapy. We quantified the response to chemotherapy clinically and pathologically and determined histological and molecular tumour characteristics. We assessed changes in the expression of Bcl-2, ER, P53 HER2 and Ki-67. Association with response and outcome was tested for all parameters. The experimental results showed 15 clinical (17%) and three (3%) pathological complete remissions. There were 18 (20%) clinical vs 29 (33%) pathological nonresponders. The expression of most markers was similar before and after chemotherapy. Only Ki-67 was significantly decreased after chemotherapy. Factors correlated with response were: large tumour size, ER negativity, high Ki-67 count and positive P53 status. Tumour response and marker expression did not predict disease-free or overall survival. In conclusion, clinical and pathological response assessments are poorly associated. Proliferation decreases significantly after chemotherapy. ER negativity and a high proliferation index are associated with better response. HER2 status does not predict response, and outcome is not related to tumour response. |
format | Text |
id | pubmed-2747533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27475332009-09-21 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Faneyte, I F Schrama, J G Peterse, J L Remijnse, P L Rodenhuis, S van de Vijver, M J Br J Cancer Molecular and Cellular Pathology The aim of this study was to provide a better insight into breast cancer response to chemotherapy. Chemotherapy improves outcome in breast cancer patients. The effect of cytotoxic treatment cannot be predicted for individual patients. Therefore, the identification of tumour characteristics associated with tumour response and outcome is of great clinical interest. We studied 97 patients, who received anthracycline-based neoadjuvant chemotherapy. Tumour samples were taken prior to and after chemotherapy. We quantified the response to chemotherapy clinically and pathologically and determined histological and molecular tumour characteristics. We assessed changes in the expression of Bcl-2, ER, P53 HER2 and Ki-67. Association with response and outcome was tested for all parameters. The experimental results showed 15 clinical (17%) and three (3%) pathological complete remissions. There were 18 (20%) clinical vs 29 (33%) pathological nonresponders. The expression of most markers was similar before and after chemotherapy. Only Ki-67 was significantly decreased after chemotherapy. Factors correlated with response were: large tumour size, ER negativity, high Ki-67 count and positive P53 status. Tumour response and marker expression did not predict disease-free or overall survival. In conclusion, clinical and pathological response assessments are poorly associated. Proliferation decreases significantly after chemotherapy. ER negativity and a high proliferation index are associated with better response. HER2 status does not predict response, and outcome is not related to tumour response. Nature Publishing Group 2003-02-10 2003-02-10 /pmc/articles/PMC2747533/ /pubmed/12569384 http://dx.doi.org/10.1038/sj.bjc.6600749 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular and Cellular Pathology Faneyte, I F Schrama, J G Peterse, J L Remijnse, P L Rodenhuis, S van de Vijver, M J Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome |
title | Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome |
title_full | Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome |
title_fullStr | Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome |
title_full_unstemmed | Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome |
title_short | Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome |
title_sort | breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome |
topic | Molecular and Cellular Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747533/ https://www.ncbi.nlm.nih.gov/pubmed/12569384 http://dx.doi.org/10.1038/sj.bjc.6600749 |
work_keys_str_mv | AT faneyteif breastcancerresponsetoneoadjuvantchemotherapypredictivemarkersandrelationwithoutcome AT schramajg breastcancerresponsetoneoadjuvantchemotherapypredictivemarkersandrelationwithoutcome AT petersejl breastcancerresponsetoneoadjuvantchemotherapypredictivemarkersandrelationwithoutcome AT remijnsepl breastcancerresponsetoneoadjuvantchemotherapypredictivemarkersandrelationwithoutcome AT rodenhuiss breastcancerresponsetoneoadjuvantchemotherapypredictivemarkersandrelationwithoutcome AT vandevijvermj breastcancerresponsetoneoadjuvantchemotherapypredictivemarkersandrelationwithoutcome |